This decision to remove REMS comes one year after the FDA loosened REMS requirements and removed the site mandate for CAR T educational and training materials because they deemed the product label...

Scientists have made remarkable progress in understanding the thousands of genes inside our cells and the link they may have to cancer. Researchers continue to discover patient-specific...

Successfully complete new hire orientation Complete training to gain competency in SA, RxClaims and MSA Toolbox Attend Prime intern activities, such as volunteer opportunities and intern lunch and...

Therapy options Keytruda (Pembrolizumab) Adstiladrin (nadofaragene firadenovec-vncg) Anktiva (nogapendekin alfa inbakicept-pmln) + BCG Study KEYNOTE-057, phase 2, open label; 5-year follow-up;...

References National Cancer Institute. (2020, October 26). Radiopharmaceuticals: radiation therapy enters the molecular age....

Medication insights: teprotumumab-trbw (Tepezza) The U.S. Food and Drug Administration (FDA) first approved teprotumumab-trbw (Tepezza) in January 2020 for the treatment of thyroid eye disease...

Effective: January 2021 Terms of use IF YOU ARE EXPERIENCING A MEDICAL EMERGENCY, DIAL 911 AND/OR SEEK IMMEDIATE ATTENTION FROM A HEALTH CARE PROVIDER. THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE....

Event features Prime's Health Outcomes team

Forbes

Cover image for Prime Therapeutics prioritizes patient-centered care, stays ahead of oncology trends Prime simplifies the cancer care pathway through innovative solutions that help manage complex...

Sept. 27, 2024 - ustekinumab-aauz (Otulfi) Fresenius Kabi has received FDA approval for Otulfi as a biosimilar to ustekinumab (Stelara). This human interleukin (IL)-12 and IL-23 antagonist is...

Zabrina Watkins Our passion Our people “At Prime we’re committed to creating an open, inclusive culture that’s purpose-oriented and focused on providing meaningful work for our employees. To do...

Oncology Insights On May 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to intravenous Imdelltra™ (tarlatamab) for the treatment of adults with relapsed/refractory...

Traditional Feb. 28, 2025 – denosumab-bmwo (Osenvelt) BLA approval; denosumab-bmwo (Osenvelt) is a biosimilar to reference drug denosumab (Xgeva) RANK ligand inhibitor Osenvelt is indicated for (1)...

Tennessee pharmacies In accordance with Texas Senate Bill 1236, Prime Therapeutics provides Texas-based pharmacies with secure online access to their pharmacy benefit network contracts that were...

Home Other Navigation Pharmacy + Providers Commercial Formularies PrimeChoice Accord™ Formulary PrimeChoice Accord™ Formulary Updates NetResults™ A-Series Prescription Drug Guide NetResults™...

Managed Markets Insight & Technology (MMIT)

New or expanded indications March 12, 2025 – fluocinolone acetonide intravitreal implant (Iluvien) Alimera; corticosteroid; supplemental NDA (sNDA) approved for consolidation of labeling of...

This form is specifically used to request a check reissue. For remittance requests, please use the following link: Pharmacy remittance request - Prime Therapeutics LLC. Prime Therapeutics cannot...

Disclaimer THIS WEBSITE IS AN OPTIONAL RESOURCE FOR HEALTH CARE PROVIDERS ONLY. IF YOU ARE NOT A HEALTH CARE PROVIDER OR AUTHORIZED PROFESSIONAL USER, YOU ARE NOT TO USE THIS SITE AT ALL AND ARE...